Sebastian Peter1. 1. University of the West Indies, Nassau, Bahamas. samaxe@aol.com
Abstract
BACKGROUND/AIM: Therapy for idiopathic reactive hypoglycemia is ineffective and impractical. Acarbose, an alpha-glucosidase inhibitor, decreases the absorbed glucose load. This study was done to determine the efficacy of acarbose in this syndrome. METHODS: Six patients with symptoms suggestive of postprandial hypoglycemia were chosen consecutively. Three-hour oral glucose tolerance tests using 75 g of glucose were done on each patient. The patients were then treated with acarbose with each meal. RESULTS: All patients had symptomatic hypoglycemia during testing. After 4 weeks of acarbose therapy, all patients were asymptomatic on a regular diet. CONCLUSION: Acarbose is efficacious in the management of idiopathic reactive hypoglycemia. Copyright 2003 S. Karger AG, Basel
BACKGROUND/AIM: Therapy for idiopathic reactive hypoglycemia is ineffective and impractical. Acarbose, an alpha-glucosidase inhibitor, decreases the absorbed glucose load. This study was done to determine the efficacy of acarbose in this syndrome. METHODS: Six patients with symptoms suggestive of postprandial hypoglycemia were chosen consecutively. Three-hour oral glucose tolerance tests using 75 g of glucose were done on each patient. The patients were then treated with acarbose with each meal. RESULTS: All patients had symptomatic hypoglycemia during testing. After 4 weeks of acarbose therapy, all patients were asymptomatic on a regular diet. CONCLUSION:Acarbose is efficacious in the management of idiopathic reactive hypoglycemia. Copyright 2003 S. Karger AG, Basel
Authors: Rodrigo O Moreira; Rustan B M Moreira; Nikolas A M Machado; Tatiana B Gonçalves; Walmir F Coutinho Journal: Obes Surg Date: 2008-06-20 Impact factor: 4.129